Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a $12M Series D financing, bringing the total round to $76M. Participants include Accuitive Medical Ventures, Investor Growth Capital, Thomas McNerney, Venrock, Versant Ventures and U.S. Venture Partners.
Thanx for your patience as we catch-up.

Awarepoint (San Diego, CA) a commercial-stage hospital data analysis and automation software suite focused on real-time patient care progression, closed a $27M Series F financing. Participants include Kleiner Perkins, Top Tier Capital Partners, Cardinal Partners, Venrock and Jafco Ventures.
Thanx for your patience as we catch-up.

Advance Medical (Palo Alto, CA) a commercial-stage company focused on the Latin American markets to delivery of an aesthetic medical device for the reduction of fat and other products, closed a $6M Series A financing. Participants include Venrock.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $24M million Series C financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.

Pathwork Diagnostics (Redwood City, CA) a commercial-stage molecular diagnostics company focused on tumor RNA expression patterns, closed a $30M Series C financing, it announced. Participants include Alta Partners, Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.

Zeltiq (Pleasanton, CA) a commercial-stage medical device company focused on lipolysis for fat reduction and other dermatological applications, closed a $25M Series D financing. Participants include Aisling Capital, Venrock, Frazier Healthcare Ventures and Advanced Technology Ventures.

Castlight Health (San Francisco) a development-stage consumer facing personalized healthcare platform, closed a $60M Series C financing. Participants include Morgan Stanley Investment Management, Wellcome Trust, US Venture Partners, Cleveland Clinic, Maverick Capital, Oak Investment Partners and Venrock.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a Series D financing. Participants include Venrock, Emergent Medical Partners, Investor Growth Capital, Thomas McNerney and Partners, U.S. Venture Partners and Versant Ventures.

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb